BioSpace News Archive

AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the commencement of an investigator initiated Phase 2 study at UC San Francisco (UCSF) for its novel inhaled form of sirolimus, LAM-001, for the treatment of bronchiolitis obliterans syndrome (BOS) in patients post-lung transplant.

Mitsubishi Tanabe Pharma Canada, a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® Oral Suspension is now covered under British Columbia PharmaCare for the treatment of people living with amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.

The funding from the National Institutes for Health and the Washington State Andy Hill CARE Fund will fuel drug discovery efforts leveraging Talus Bio’s proprietary discovery platform

Gilead Sciences, Inc. (Nasdaq: GILD) and Meharry Medical College today announced the publication of a new supplemental issue of Meharry Medical College’s Journal of Health Care for the Poor and Underserved.

JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, will present prior data on Jan101’s randomized double blind placebo-controlled trial in diabetic neuropathy patients.

Astrocyte Pharmaceuticals Inc., a clinical-stage drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced an oversubscribed pre-Series B Bridge financing round of over $6M that was led by Dreavent Capital, and joined by the Alzheimer’s Drug Discovery Foundation, and other investors

Psychemedics Corporation announced the grant of inducement awards to its newly appointed President and Chief Executive Officer, Brian Hullinger, upon his entering into employment with the Company in accordance with Nasdaq Listing Rule 5635.

Boston Immune Technologies and Therapeutics, Inc. (BITT) announced today that the Food and Drug Administration (FDA) has cleared BITT’s Investigational New Drug application (IND) for a Phase I trial of BITT2101 (anti-TNFR2) in patients with relapsed or refractory Non-Hodgkin’s lymphomas.

Viracta Therapeutics, Inc. announced that, in connection with the appointment of Darrel P. Cohen, M.D., Ph.D. as Viracta’s new Chief Medical Officer, the Compensation Committee of Viracta’s Board of Directors granted Dr. Cohen a non-qualified stock option to purchase 235,000 shares of common stock under Viracta’s 2021 Inducement Equity Incentive Plan.

Deciphera Pharmaceuticals, Inc. announced that in connection with the hiring of Kevin Brodbeck, Senior Vice President and Chief Technical Officer, the Compensation Committee of Deciphera’s Board of Directors approved the grant of a stock option to purchase 89,200 shares of Deciphera’s common stock, 44,600 restricted stock units and a special grant of 15,000 RSUs to Mr. Brodbeck with a grant date of August 15, 2023.